The broad, long-term objective of this application is to improve the prognosis of patients with unresectable hepatocellular carcinoma (HCC). Magnetic resonance imaging (MRI) is proposed to monitor transcatheter arterial chemoembolization (TACE) of patients with HCC. A 4-dimensional transcatheter intraarterial perfusion weighted (TRIP)-MRI technique, using 3 spatial and 1 time dimension, will be used to measure quantitative changes in tumor perfusion at the time of therapy. These quantitative, absolute changes in perfusion will be correlated with clinical outcomes, x-ray digital subtraction angiography (DSA) endpoints, and tumor angiogenic markers on tissue specimens. The rationale is to determine the pivotal role that perfusion plays during TACE as a means of determining endpoints for therapy. Studies will be performed within the same prospective cohort of 100 patients with HCC already scheduled to undergo TACE using a hybrid MR-interventional radiology DSA procedure suite. This suite contains both a 1.5T MRI scanner and a DSA unit.
Specific Aim 1 will correlate tumor perfusion changes during TACE with clinical outcomes. It is hypothesized that baseline and interval reductions in quantitative 4D TRIP-MRI perfusion levels during TACE can predict future clinical outcomes. These clinical outcomes will be assessed by conventional anatomic size changes on MRI; functional changes in water mobility using an improved diffusion weighted MRI technique; survival; and toxicity. The health relevance will be to optimize TACE outcomes by measuring absolute perfusion changes for therapy.
Specific Aim 2 will correlate DSA endpoints during TACE with perfusion changes and clinical outcomes. It is hypothesized that DSA endpoints during TACE do not correlate with quantitative 4D TRIP-MRI perfusion changes and do not predict clinical outcomes. The health relevance is to use external objective standards to see if a specific DSA endpoint can and should be targeted during therapy.
Specific Aim 3 will correlate perfusion changes during TACE with tumor angiogenesis and clinical outcomes. Angiogenic proteins-- vascular endothelial growth factor (VEGF) and hypoxia inducible factor-11 (HIF-11) will be measured on pre-TACE liver biopsy specimens and on available liver explants. It is hypothesized that baseline tissue levels of VEGF and HIF-11 correlate with clinical outcomes after TACE; and that 4D TRIP-MRI perfusion changes during TACE predict future expression of tissue VEGF and HIF-11 on liver explants.

Public Health Relevance

The health relevance is to see how baseline tissue angiogenic markers affect outcome and to determine which TACE endpoints are most likely to induce angiogenesis. The relevance to public health is to determine the central role that blood flow to tumors plays during treatment of liver cancer. We postulate that measurement of this blood flow during treatment can be used to help predict response to therapy. This information might improve the prognosis of future patients with liver cancer. ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
1R01CA126809-01A2
Application #
7526894
Study Section
Medical Imaging Study Section (MEDI)
Program Officer
Farahani, Keyvan
Project Start
2008-09-01
Project End
2012-07-31
Budget Start
2008-09-01
Budget End
2009-07-31
Support Year
1
Fiscal Year
2008
Total Cost
$313,325
Indirect Cost
Name
Northwestern University at Chicago
Department
Radiation-Diagnostic/Oncology
Type
Schools of Medicine
DUNS #
005436803
City
Chicago
State
IL
Country
United States
Zip Code
60611
Li, Weiguo; Zhang, Zhuoli; Li, Kangan et al. (2015) Respiratory self-gating for free-breathing magnetization transfer MRI of the abdomen. Magn Reson Med 73:2249-54
Memon, Khairuddin; Kulik, Laura M; Lewandowski, Robert J et al. (2014) Comparative study of staging systems for hepatocellular carcinoma in 428 patients treated with radioembolization. J Vasc Interv Radiol 25:1056-66
Gordon, Andrew C; Gradishar, William J; Kaklamani, Virginia G et al. (2014) Yttrium-90 radioembolization stops progression of targeted breast cancer liver metastases after failed chemotherapy. J Vasc Interv Radiol 25:1523-32, 1532.e1-2
Salem, Riad; Mazzaferro, Vincenzo; Sangro, Bruno (2013) Yttrium 90 radioembolization for the treatment of hepatocellular carcinoma: biological lessons, current challenges, and clinical perspectives. Hepatology 58:2188-97
Vouche, Michael; Kulik, Laura; Atassi, Rohi et al. (2013) Radiological-pathological analysis of WHO, RECIST, EASL, mRECIST and DWI: Imaging analysis from a prospective randomized trial of Y90 ýý sorafenib. Hepatology 58:1655-66
Vouche, Michael; Lewandowski, Robert J; Atassi, Rohi et al. (2013) Radiation lobectomy: time-dependent analysis of future liver remnant volume in unresectable liver cancer as a bridge to resection. J Hepatol 59:1029-36
Salem, Riad; Lewandowski, Robert J (2013) Chemoembolization and radioembolization for hepatocellular carcinoma. Clin Gastroenterol Hepatol 11:604-11; quiz e43-4
Salem, Riad; Gilbertsen, Margaret; Butt, Zeeshan et al. (2013) Increased quality of life among hepatocellular carcinoma patients treated with radioembolization, compared with chemoembolization. Clin Gastroenterol Hepatol 11:1358-1365.e1
Hickey, Ryan; Vouche, Michael; Sze, Daniel Y et al. (2013) Cancer concepts and principles: primer for the interventional oncologist-part II. J Vasc Interv Radiol 24:1167-88
Nguyen, Long H; Nguyen, Mindie H (2013) Prevention of mother-to-child transmission of hepatitis B virus: is elective cesarean section in highly viremic mothers an appropriate adjunct to immunoprophylaxis? Clin Gastroenterol Hepatol 11:1356-7

Showing the most recent 10 out of 37 publications